Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 9/20 | 0.65 |
| ▸ | RAB9A | P51151 | 9/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.65 |
| ▸ | RELA | Q04206 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8057745 | 0.88 | MAPT (0.68) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28527743 | 0.86 | MAPT (0.76) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3140270 | 0.86 | SMN1; SMN2 (0.65) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19267603 | 0.82 | RAB9A (0.72) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14640404 | 0.82 | MAPT (0.61) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4455272 | 0.81 | LMNA (0.65) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14325740 | 0.80 | MAPT (0.53) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3612694 | 0.80 | MAPT (0.67) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10061659 | 0.80 | MAPT (0.64) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2229720 | 0.79 | MAPT (0.63) | MAPTLMNANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CNR1 | MAPT 3585/4885LMNA 3001/4885NPC1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.